The other factor to consider is that Spectrum has had troubles with Fusilev:
Spectrum Pharmaceuticals (SPPI_) hasn't seen the end of Fusilev sales declines, meaning the company's already-lowered guidance for 2013 might still be too high, says Credit Suisse analyst Jason Kantor.
Kantor cut his Spectrum rating to underperform from neutral and slashed his 2013 Fusilev sales projection to $65 million from $77 million on Monday due to prescription sales data showing slack demand for the colon cancer drug.
Spectrum shares are already down 31 percent this year because the company cut its 2013 Fusilev sales guidance to $80-90 million, blaming over-stuffed wholesaler inventory and falling demand from hospitals. Fusilev sales totaled $204 million in 2012.
Market Data 
Markets 
AI
